Zentalis Pharmaceuticals的封面图片
Zentalis Pharmaceuticals

Zentalis Pharmaceuticals

生物技术研究

San Diego,California 17,162 位关注者

Developing small molecule therapeutics targeting fundamental biological pathways of cancers

关于我们

Zentalis? Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). Azenosertib is being evaluated as a monotherapy and in combination across multiple tumor types in clinical trials and has broad franchise potential. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. The Company is also leveraging its extensive experience and capabilities to translate its science to advance research on additional areas of opportunity for azenosertib outside PROC.

网站
https://www.zentalis.com
所属行业
生物技术研究
规模
51-200 人
总部
San Diego,California
类型
上市公司

地点

  • 主要

    10275 Science Center Dr

    Suite 200

    US,California,San Diego,92121

    获取路线

Zentalis Pharmaceuticals员工

动态

相似主页

查看职位

融资